Volta Labs at AACR 2025: Showcasing Advanced Targeted Sequencing Solutions for Cancer Research

The Volta Labs team is excited to announce our participation in the American Association of Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois. As the critical driver of progress against cancer, AACR brings together scientists, clinicians, and healthcare professionals to share groundbreaking advancements in cancer science and medicine.

Addressing the Sample Prep Bottleneck in Cancer Research

Cancer research demands precision, reliability, and efficiency—particularly when it comes to sample preparation for next-generation sequencing. While sequencing technologies have made remarkable strides over the past decade, the sample preparation phase has remained largely unchanged, creating a critical bottleneck in cancer genomics workflows.

At Volta Labs, we're revolutionizing this crucial step with our Callisto™ Sample Prep System, which brings the push-button experience of a sequencer to targeted sequencing applications. Our walk-away automation dramatically reduces hands-on time while delivering superior performance, scalability, and consistency—key requirements for cancer researchers pushing the boundaries of precision oncology.

Spotlight: Targeted Sequencing for Precision Oncology

At AACR 2025, we'll be showcasing our latest advancements in hybridization capture workflows, particularly for targeted sequencing applications in cancer research. The Callisto™ Sample Prep System has been optimized to support targeted panels for somatic variant detection, liquid biopsy analysis, and comprehensive tumor profiling.

The VoltaHyb™ suite of apps and kits are specifically configured to excel with hybridization capture chemistries, ensuring robust and consistent performance across various panel sizes—from focused hotspot panels to comprehensive cancer exomes. Our technology delivers:

• Exceptional performance with <3% redo rates and even GC distribution
• Cost-effective multiplexing powered by Callisto's unique system architecture
• Miniaturized workflows that reduce reagent usage and plastic waste
• Walk-away operation with no specialized training required

Bridging Short and Long-Read Cancer Applications

Cancer genomics is increasingly utilizing a mix of established, precise, short-read sequencing platforms, paired now with a wealth of novel structural variant insights enabled by long-read sequencing. The Callisto platform uniquely supports both approaches, allowing cancer researchers to seamlessly transition between targeted hybridization capture for hotspot detection and whole genome approaches for comprehensive structural variant analysis, while delivering clinical grade sample and library prep applications.

Our recent collaboration with leading cancer research institutions has demonstrated the Callisto system's ability to maintain the highest quality standards across both methodologies, ensuring researchers can access the most appropriate technology for their specific research questions.

Visit Booth #4806 at AACR 2025

We invite all AACR attendees to visit Volta Labs at Booth #4806, where our team will be demonstrating the Callisto™ Sample Prep System and discussing how our technology can enhance your cancer research workflows. Schedule a meeting with our team to discuss your specific applications and learn how Volta Labs can help eliminate the burden of method development, improve operational flexibility, and reduce risks related to manual sample handling.

Whether your research focuses on targeted sequencing for biomarker discovery, liquid biopsy for early detection, or comprehensive tumor profiling, the Volta team is ready to help you accelerate your discoveries.

‍

‍

Volta Labs is a genomics applications company transforming the way biological research and analyses are performed. Our cutting-edge digital fluidics platform maximizes performance and scalability of sample preparation while providing unparalleled consistency. We're bringing the push-button experience of a sequencer to sample prep, allowing scientists to focus on what they do best—pushing the boundaries of biology.